Share Price and Basic Stock Data
Last Updated: November 14, 2025, 12:10 pm
| PEG Ratio | -9.99 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Genpharmasec Ltd, operating in the Trading & Distributors sector, reported a market capitalization of ₹98.0 Cr and a current share price of ₹1.77. The company has showcased a progressive revenue trend, with sales increasing from ₹25.52 Cr in March 2023 to ₹33.57 Cr in March 2025, marking a growth trajectory. Trailing twelve-month (TTM) sales stood at ₹40.56 Cr, indicating a robust operational performance. Quarterly sales figures exhibited volatility, peaking at ₹14.01 Cr in March 2025, while the lowest quarterly sales were recorded at ₹5.20 Cr in June 2024. Despite fluctuations, the overall upward trend in annual sales suggests a strengthening market position. The operating profit margin (OPM) improved from 1.02% in March 2023 to 0.24% in March 2025, highlighting the company’s efforts to enhance operational efficiency. The steady growth in sales, coupled with strategic operational adjustments, positions Genpharmasec positively within its industry.
Profitability and Efficiency Metrics
Genpharmasec’s profitability metrics reflect a mixed performance over recent periods. The net profit for March 2025 reported at ₹1.23 Cr, rebounding from a loss of ₹0.17 Cr in March 2024, underscores a recovery in profitability. However, the operating profit saw a modest rise from ₹0.26 Cr in March 2023 to ₹0.08 Cr in March 2025, indicating challenges in maintaining operational profitability. The company’s return on equity (ROE) was noted at 1.90%, while return on capital employed (ROCE) stood at 3.35%, both figures suggesting a relatively low efficiency in generating returns compared to industry standards. The cash conversion cycle (CCC) improved significantly from 211.34 days in March 2023 to 146.47 days in March 2025, reflecting enhanced efficiency in managing working capital. Despite the improvements, the net profit margin of 3.65% in March 2025 remains below the sector average, indicating that Genpharmasec faces ongoing challenges in translating revenue into profit.
Balance Sheet Strength and Financial Ratios
Genpharmasec’s balance sheet reflects a complex financial landscape with total liabilities of ₹79.89 Cr as of March 2025, against total assets of ₹79.89 Cr, indicating a balanced position. The company’s equity capital rose significantly from ₹27.69 Cr in March 2023 to ₹55.37 Cr in March 2024, while reserves improved from a negative ₹12.36 Cr to ₹9.79 Cr in March 2025, illustrating a turnaround in retained earnings. The debt levels, with borrowings at ₹5.28 Cr, indicate a low leverage scenario with a total debt to equity ratio of 0.04, suggesting financial prudence. The interest coverage ratio (ICR) stood at 7.19x, well above the threshold for financial stability, indicating the company can comfortably meet its interest obligations. However, the price-to-book value (P/BV) ratio of 1.61x suggests that the stock may be trading at a premium relative to its book value, which could indicate overvaluation concerns in the context of its profitability metrics.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genpharmasec Ltd indicates a significant shift in ownership dynamics. Promoter holdings have declined from 59.96% in March 2023 to 29.98% by March 2025, suggesting a potential dilution of control or strategic divestment. In contrast, public shareholding increased from 40.04% to 70.02% over the same period, reflecting growing investor interest and confidence in the company’s prospects. The number of shareholders has also risen from 49,760 in March 2023 to 1,09,080 in March 2025, indicating a broader base of retail investors. Such changes could enhance liquidity but may also raise concerns about the stability of management control. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may indicate limited institutional confidence in the stock, which could impact its market performance. Overall, the evolving shareholding structure points to a shift towards greater public participation, which can be both a positive and a risk factor for long-term stability.
Outlook, Risks, and Final Insight
Looking ahead, Genpharmasec Ltd faces a mix of opportunities and challenges. The recent uptick in sales and a recovering net profit position suggest potential for continued growth, especially if the company can maintain its revenue trajectory and improve profitability metrics. However, risks remain, particularly regarding operational efficiency and the management of fluctuating expenses, which have historically impacted margins. Furthermore, the declining promoter stake raises questions about long-term strategic direction and control. The company must also navigate market volatility and economic conditions that could affect consumer demand in the trading sector. A focus on enhancing operational efficiencies and stabilizing profit margins will be crucial for sustaining investor confidence and attracting institutional interest. In summary, while Genpharmasec has shown resilience and growth, it must address underlying operational challenges to secure its position in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genpharmasec Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Minal Industries Ltd | 68.9 Cr. | 3.59 | 5.59/3.20 | 45.9 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 12.6 Cr. | 14.3 | 18.6/13.0 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 6.37 Cr. | 70.0 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 93.7 Cr. | 45.7 | 49.8/10.2 | 92.8 | 15.0 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| MRP Agro Ltd | 107 Cr. | 96.0 | 174/84.4 | 15.1 | 30.6 | 0.00 % | 39.2 % | 30.3 % | 10.0 |
| Industry Average | 11,409.25 Cr | 164.48 | 101.45 | 117.47 | 0.39% | 15.44% | 8.88% | 7.74 |
Quarterly Result
| Metric | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.22 | 7.86 | 6.38 | 10.20 | 5.20 | 6.03 | 8.48 | 14.01 | 12.04 |
| Expenses | 6.01 | 7.89 | 6.37 | 10.21 | 5.00 | 5.90 | 7.74 | 15.01 | 11.10 |
| Operating Profit | 0.21 | -0.03 | 0.01 | -0.01 | 0.20 | 0.13 | 0.74 | -1.00 | 0.94 |
| OPM % | 3.38% | -0.38% | 0.16% | -0.10% | 3.85% | 2.16% | 8.73% | -7.14% | 7.81% |
| Other Income | 0.06 | 0.15 | 0.14 | 0.31 | 0.57 | 0.75 | 0.81 | 0.94 | 0.69 |
| Interest | 0.06 | 0.07 | 0.00 | 0.16 | 0.10 | 0.07 | 0.16 | 0.11 | 0.12 |
| Depreciation | 0.01 | 0.00 | 0.12 | 0.03 | 0.16 | 0.30 | 0.10 | 0.26 | 0.27 |
| Profit before tax | 0.20 | 0.05 | 0.03 | 0.11 | 0.51 | 0.51 | 1.29 | -0.43 | 1.24 |
| Tax % | -420.00% | 80.00% | -100.00% | 345.45% | 35.29% | -39.22% | 39.53% | -37.21% | 2.42% |
| Net Profit | 1.05 | 0.01 | 0.06 | -0.27 | 0.33 | 0.70 | 0.78 | -0.27 | 1.22 |
| EPS in Rs | 0.02 | 0.00 | 0.00 | -0.00 | 0.01 | 0.01 | 0.01 | -0.00 | 0.02 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genpharmasec Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 12.04 Cr.. The value appears to be declining and may need further review. It has decreased from 14.01 Cr. (Mar 2025) to 12.04 Cr., marking a decrease of 1.97 Cr..
- For Expenses, as of Jun 2025, the value is 11.10 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.01 Cr. (Mar 2025) to 11.10 Cr., marking a decrease of 3.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.94 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Mar 2025) to 0.94 Cr., marking an increase of 1.94 Cr..
- For OPM %, as of Jun 2025, the value is 7.81%. The value appears strong and on an upward trend. It has increased from -7.14% (Mar 2025) to 7.81%, marking an increase of 14.95%.
- For Other Income, as of Jun 2025, the value is 0.69 Cr.. The value appears to be declining and may need further review. It has decreased from 0.94 Cr. (Mar 2025) to 0.69 Cr., marking a decrease of 0.25 Cr..
- For Interest, as of Jun 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.11 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 0.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.26 Cr. (Mar 2025) to 0.27 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.24 Cr.. The value appears strong and on an upward trend. It has increased from -0.43 Cr. (Mar 2025) to 1.24 Cr., marking an increase of 1.67 Cr..
- For Tax %, as of Jun 2025, the value is 2.42%. The value appears to be increasing, which may not be favorable. It has increased from -37.21% (Mar 2025) to 2.42%, marking an increase of 39.63%.
- For Net Profit, as of Jun 2025, the value is 1.22 Cr.. The value appears strong and on an upward trend. It has increased from -0.27 Cr. (Mar 2025) to 1.22 Cr., marking an increase of 1.49 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.02. The value appears strong and on an upward trend. It has increased from 0.00 (Mar 2025) to 0.02, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:16 am
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | 25.52 | 30.41 | 33.57 | 67.17 |
| Expenses | 25.26 | 30.37 | 33.49 | 66.95 |
| Operating Profit | 0.26 | 0.04 | 0.08 | 0.22 |
| OPM % | 1.02% | 0.13% | 0.24% | 0.33% |
| Other Income | 0.10 | 0.66 | 3.06 | 2.90 |
| Interest | 0.06 | 0.41 | 0.45 | 0.62 |
| Depreciation | 0.02 | 0.04 | 0.81 | 1.19 |
| Profit before tax | 0.28 | 0.25 | 1.88 | 1.31 |
| Tax % | -300.00% | 168.00% | 34.57% | |
| Net Profit | 1.12 | -0.17 | 1.23 | 0.55 |
| EPS in Rs | 0.02 | -0.00 | 0.02 | 0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2023-2024 | 2024-2025 |
|---|---|---|
| YoY Net Profit Growth (%) | -115.18% | 823.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | 938.71% |
Genpharmasec Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 1769% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | -22% |
| 3 Years: | -9% |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:36 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Debtor Days | 81.67 | 109.22 | 147.21 |
| Inventory Days | 151.06 | 133.17 | 101.29 |
| Days Payable | 21.38 | 35.85 | 102.03 |
| Cash Conversion Cycle | 211.34 | 206.54 | 146.47 |
| Working Capital Days | 199.09 | 213.17 | 141.26 |
| ROCE % | 1.52% | 3.32% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 0.01 | -0.01 |
| Diluted EPS (Rs.) | 0.01 | -0.01 |
| Cash EPS (Rs.) | 0.03 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.18 | 1.17 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.18 | 1.17 |
| Revenue From Operations / Share (Rs.) | 0.60 | 0.54 |
| PBDIT / Share (Rs.) | 0.05 | 0.01 |
| PBIT / Share (Rs.) | 0.04 | 0.01 |
| PBT / Share (Rs.) | 0.03 | 0.00 |
| Net Profit / Share (Rs.) | 0.02 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 0.02 | 0.00 |
| PBDIT Margin (%) | 9.27 | 2.30 |
| PBIT Margin (%) | 6.86 | 2.16 |
| PBT Margin (%) | 5.57 | 0.82 |
| Net Profit Margin (%) | 3.65 | -0.55 |
| NP After MI And SOA Margin (%) | 3.65 | -0.41 |
| Return on Networth / Equity (%) | 1.88 | -0.19 |
| Return on Capital Employeed (%) | 3.30 | 0.96 |
| Return On Assets (%) | 1.54 | -0.17 |
| Long Term Debt / Equity (X) | 0.04 | 0.04 |
| Total Debt / Equity (X) | 0.04 | 0.04 |
| Asset Turnover Ratio (%) | 0.44 | 0.00 |
| Current Ratio (X) | 2.86 | 15.16 |
| Quick Ratio (X) | 2.03 | 11.89 |
| Inventory Turnover Ratio (X) | 0.10 | 0.00 |
| Interest Coverage Ratio (X) | 7.19 | 1.72 |
| Interest Coverage Ratio (Post Tax) (X) | 3.83 | 0.58 |
| Enterprise Value (Cr.) | 102.65 | 108.00 |
| EV / Net Operating Revenue (X) | 3.04 | 3.55 |
| EV / EBITDA (X) | 32.83 | 153.89 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 4.06 |
| Price / BV (X) | 1.61 | 1.92 |
| Price / Net Operating Revenue (X) | 3.10 | 4.06 |
| EarningsYield | 0.01 | 0.00 |
After reviewing the key financial ratios for Genpharmasec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 3. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.18. It has increased from 1.17 (Mar 24) to 1.18, marking an increase of 0.01.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.18. It has increased from 1.17 (Mar 24) to 1.18, marking an increase of 0.01.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.60. It has increased from 0.54 (Mar 24) to 0.60, marking an increase of 0.06.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 2. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For PBDIT Margin (%), as of Mar 25, the value is 9.27. This value is below the healthy minimum of 10. It has increased from 2.30 (Mar 24) to 9.27, marking an increase of 6.97.
- For PBIT Margin (%), as of Mar 25, the value is 6.86. This value is below the healthy minimum of 10. It has increased from 2.16 (Mar 24) to 6.86, marking an increase of 4.70.
- For PBT Margin (%), as of Mar 25, the value is 5.57. This value is below the healthy minimum of 10. It has increased from 0.82 (Mar 24) to 5.57, marking an increase of 4.75.
- For Net Profit Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 5. It has increased from -0.55 (Mar 24) to 3.65, marking an increase of 4.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 3.65. This value is below the healthy minimum of 8. It has increased from -0.41 (Mar 24) to 3.65, marking an increase of 4.06.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 15. It has increased from -0.19 (Mar 24) to 1.88, marking an increase of 2.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.30. This value is below the healthy minimum of 10. It has increased from 0.96 (Mar 24) to 3.30, marking an increase of 2.34.
- For Return On Assets (%), as of Mar 25, the value is 1.54. This value is below the healthy minimum of 5. It has increased from -0.17 (Mar 24) to 1.54, marking an increase of 1.71.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.00 (Mar 24) to 0.44, marking an increase of 0.44.
- For Current Ratio (X), as of Mar 25, the value is 2.86. This value is within the healthy range. It has decreased from 15.16 (Mar 24) to 2.86, marking a decrease of 12.30.
- For Quick Ratio (X), as of Mar 25, the value is 2.03. This value exceeds the healthy maximum of 2. It has decreased from 11.89 (Mar 24) to 2.03, marking a decrease of 9.86.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.10, marking an increase of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.19. This value is within the healthy range. It has increased from 1.72 (Mar 24) to 7.19, marking an increase of 5.47.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.83. This value is within the healthy range. It has increased from 0.58 (Mar 24) to 3.83, marking an increase of 3.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 102.65. It has decreased from 108.00 (Mar 24) to 102.65, marking a decrease of 5.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has decreased from 3.55 (Mar 24) to 3.04, marking a decrease of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.83. This value exceeds the healthy maximum of 15. It has decreased from 153.89 (Mar 24) to 32.83, marking a decrease of 121.06.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.10. This value exceeds the healthy maximum of 3. It has decreased from 4.06 (Mar 24) to 3.10, marking a decrease of 0.96.
- For Price / BV (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 1.92 (Mar 24) to 1.61, marking a decrease of 0.31.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.10. This value exceeds the healthy maximum of 3. It has decreased from 4.06 (Mar 24) to 3.10, marking a decrease of 0.96.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genpharmasec Ltd:
- Net Profit Margin: 3.65%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.3% (Industry Average ROCE: 15.44%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.88% (Industry Average ROE: 8.88%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.03
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 159 (Industry average Stock P/E: 101.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.65%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises Co-Operative Society Ltd., Mumbai Maharashtra 400101 | compliance@genpharmasec.com www.genpharmasec.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sohan Chaturvedi | WholeTime Director & CFO |
| Mrs. Sneha Sadhwani | Non Exe.Non Ind.Director |
| Mr. Rajesh Sadhwani | Non Exe.Non Ind.Director |
| Mr. Siddhesh Shende | Independent Director |
| Mr. Mayur Bhatt | Independent Director |
| Mr. Sachin Aphandkar | Independent Director |